A nutritional composition for regulating immunity and its uses

By combining ω-6 polyunsaturated fatty acids and casein phosphopeptides, this method promotes T cell development and activation, regulates inflammatory factors, and increases the number and activity of immune cells. This addresses the issues of immune system construction and functional regulation in specific populations, achieving comprehensive immunity enhancement.

CN123100826APending Publication Date: 2026-11-17HEILONGJIANG FEIHE DAIRY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611508811.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing nutritional compositions are unable to effectively target the immune system development and functional regulation of specific populations such as infants, children, and the elderly, resulting in weakened immunity and failing to meet the immune nutrition needs of people throughout their entire life cycle.

Method used

Develop a nutritional composition containing ω-6 polyunsaturated fatty acids such as dihomeno-gamma-linolenic acid and casein phosphopeptide, which are combined in a specific ratio to promote T cell development and activation, regulate the expression of inflammatory factors, increase the number and activity of innate immune cells, and achieve comprehensive immune system construction and functional regulation.

Benefits of technology

Through the synergistic effect of ω-6 polyunsaturated fatty acids and casein phosphopeptides, it promotes T cell development and activation, regulates inflammatory factors, and increases the number and activity of immune cells, thereby achieving comprehensive immunity enhancement. It is suitable for people throughout their entire life cycle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention belongs to the field of nutritional research technology and relates to a nutritional composition for regulating immunity and its uses. The nutritional composition provided by this invention comprises the following two essential components: i) ω-6 polyunsaturated fatty acids, wherein the ω-6 polyunsaturated fatty acids include at least dihoxy-γ-linolenic acid; ii) casein phosphopeptide; and, in the nutritional composition, the mass ratio of dihoxy-γ-linolenic acid to casein phosphopeptide is 1:(1-3100). The combination of ω-6 polyunsaturated fatty acids such as dihoxy-γ-linolenic acid and casein phosphopeptide can promote the comprehensive construction and functional regulation of adaptive and innate immune systems, with T cell development and activation as the core.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of nutritional research technology and relates to a nutritional composition for regulating immunity and its uses. Background Technology

[0002] The immune system is the core defense system of the human body, responsible for resisting the invasion of external pathogens, clearing abnormal cells, and maintaining homeostasis. Its functional state directly determines a person's health level and disease resistance. Normal immune function effectively identifies and blocks the invasion of pathogenic microorganisms such as bacteria, viruses, and fungi, reducing the risk of infectious diseases. It also participates in the repair of bodily damage, metabolic regulation, and cell apoptosis control, playing a crucial role in preventing chronic inflammation, autoimmune diseases, and malignant lesions. Weakened immunity leads to a comprehensive decline in the body's defense, surveillance, and clearance functions, manifesting as susceptibility to colds, frequent infections with prolonged illness, and extended recovery periods. Long-term immune imbalance can also induce various health problems, seriously affecting quality of life and lifespan. Therefore, maintaining stable and appropriate immune function is a core foundation for ensuring human health.

[0003] In terms of population distribution, infants, children, and the elderly are high-risk groups for weakened immunity due to their physiological development and declining bodily functions, and generally exhibit significant immune deficiencies and health risks. The immune system of infants is not yet fully developed, and the functions of immune organs and cells are incomplete. As the passive immunity passed from the mother gradually fades, while their own active immunity is not yet fully established, infants have extremely weak resistance to external pathogens and are prone to infections of the respiratory, digestive, and other systems, with symptoms easily worsening and recurring. Children are in a period of rapid growth and development, and their immune system is still gradually maturing. Factors such as an unbalanced diet, insufficient outdoor activity, and academic pressure often lead to fluctuations in immune function, manifesting as decreased disease resistance, imbalance between nutrient absorption and immune development, and long-term weakened immunity will directly restrict their normal growth and development. As the body ages naturally, the elderly experience atrophy of immune organs, a decrease in the number and activity of immune cells, and a significant decline in immune response. This group belongs to the primary immune function decline population. Not only does this group have a significantly increased risk of infection, but they also experience more complications and a poorer prognosis after infection. At the same time, their weakened immune surveillance function further increases the probability of developing chronic diseases and degenerative changes.

[0004] It is evident that immune dysfunction has become a prominent pain point affecting health throughout the entire life cycle. Current interventions to boost immunity in specific populations such as infants, children, and the elderly suffer from insufficient targeting, limited effectiveness, and poor adaptability, failing to meet the immune nutritional needs of these special physiological stages. Therefore, there is an urgent need to develop nutritional compositions that can safely and effectively regulate and enhance immune function for people throughout their entire life cycle. Scientific nutritional interventions can compensate for immune deficiencies and improve immune status, providing crucial technological support for health protection for all populations, especially infants, children, and the elderly.

[0005] Dihomo-gamma-linolenic acid (DGLA, C20:3n-6) is a polyunsaturated fatty acid found in breast milk. In colostrum, it accounts for approximately 0.78% of the total fatty acids, comparable to docosahexaenoic acid (DHA). However, due to the limited activity of Δ6-desaturase in the human body, the endogenous synthesis of DGLA is restricted. Nevertheless, DGLA has several potential health-promoting effects, including: 1) DGLA can be integrated into neuronal and glial cell membrane phospholipids, thereby inhibiting the overactivation of microglia and playing a role in regulating neuroinflammation, neuronal proliferation, and differentiation; 2) As a precursor to anti-inflammatory substances such as prostaglandin E1 (PGE1) and 15-hydroxyeicosatetrienoic acid (15-HETrE), DGLA can antagonize pro-inflammatory factors derived from arachidonic acid (AA), thus playing a potential role in regulating inflammatory responses and maintaining immune homeostasis; 3) DGLA may also have a positive impact on cardiovascular health (cite reference 1).

[0006] Milk bioactive peptides play multiple important roles in human health and physiological regulation, such as antibacterial, antioxidant, antithrombotic, immune-modulating, and mineral-binding functions, and are therefore considered important functional components for promoting health in the food and pharmaceutical industries. Casein phosphopeptides (CPPs) are a group of bioactive peptides involved in multiple functional roles and are used worldwide as nutritional supplements, with functions such as promoting mineral absorption, influencing bone growth, and enhancing immunity. For example, cited reference 2 discloses that casein phosphopeptides and Bifidobacterium probiotics can work together to improve human immunity. Cited reference 3 discloses a highly soluble functional composition with immune-enhancing properties, the raw materials of which include whey protein, casein phosphopeptides, and solubilizing ingredients.

[0007] References:

[0008] Reference 1: Chen, Lina. The relationship between hyperglycemic γ-linolenic acid and stroke risk: a systematic review and meta-analysis [D]. Jilin University, 2025.

[0009] Reference 2: CN117441900B;

[0010] Reference 3: CN114831317B. Summary of the Invention

[0011] The problem the invention aims to solve

[0012] Addressing the immune enhancement needs of people throughout their entire life cycle, particularly the immune system construction and functional regulation needs of specific populations such as infants, children, and the elderly, this invention has conducted extensive research and aims to develop a nutritional composition based on a combination of ω-6 polyunsaturated fatty acids, such as dihoi-γ-linolenic acid, naturally found in breast milk and cow's milk, and casein phosphopeptides. These two components synergistically construct and improve an immune regulatory system centered on T cells. Specifically, this involves building an immune improvement system with T cells at its core, encompassing "whole-chain regulation + cell linkage." This addresses the functional deficiencies of T cells themselves and increases the number of innate immune cells through T cell linkage, ultimately achieving a systematic, synergistic, and lasting improvement in overall immunity. This provides a more precise and effective nutritional intervention plan for immunocompromised individuals and is suitable for long-term use by people throughout their entire life cycle.

[0013] Solution for solving the problem

[0014] To address the aforementioned technical problems, the present invention provides the following technical solution:

[0015] [1]. A nutritional composition comprising the following two essential components:

[0016] i) ω-6 polyunsaturated fatty acids, wherein the ω-6 polyunsaturated fatty acids include at least dihomo-γ-linolenic acid;

[0017] ii) Casein phosphopeptides;

[0018] Furthermore, in the nutritional composition, the mass ratio of the dihydro-γ-linolenic acid to the casein phosphopeptide is 1:(1-3100).

[0019] [2]. The nutritional composition according to [1], wherein the ω-6 polyunsaturated fatty acid is provided in the form of an oil containing it.

[0020] [3]. The nutritional composition according to [1] or [2], wherein the casein phosphopeptide comprises at least one casein phosphopeptide derived from cow's milk and sheep's milk.

[0021] [4]. The nutritional composition according to any one of [1]-[3], wherein the carbon chain length of the ω-6 polyunsaturated fatty acid is 18-22 carbon atoms.

[0022] [5]. The nutritional composition according to any one of [1]-[4], wherein the ω-6 polyunsaturated fatty acid further includes at least one of linoleic acid, γ-linolenic acid and arachidonic acid.

[0023] [6]. Use of any of the nutritional compositions according to [1]-[5] in the preparation of products that help enhance immunity; wherein the help enhances immunity includes help in the construction and functional regulation of the immune system.

[0024] [7]. According to the use described in [6], the ability to enhance immunity includes at least one of promoting T cell development, promoting T cell activation, balancing inflammatory factor levels, and increasing the number of innate immune cells.

[0025] [8]. According to the use described in [6] or [7], wherein the immune-enhancing effect has one or more of the following (I) to (IV):

[0026] (I) Increase the expression levels of genes RAG1 and / or RAG2;

[0027] (II) Increase the expression levels of genes ZAP70 and / or IFNGR1;

[0028] (III) Decrease TNF-α levels and / or increase IL-12α levels;

[0029] (IV) Increase the number of neutrophils and / or macrophages.

[0030] [9]. Use according to any one of [6]-[8], wherein the product is solid or liquid.

[0031]

[10] . Use according to any one of [6]-[9], wherein the product contains any one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives and any acceptable excipients.

[0032] The effects of the invention

[0033] This invention proposes for the first time that the combination of ω-6 polyunsaturated fatty acids, such as dihomo-γ-linolenic acid, and casein phosphopeptide has a synergistic effect on promoting the construction and functional regulation of the body's immune system, with T cell development and activation as the core. When the two are combined in a certain ratio, they can not only promote the development and activation of T cells, but also regulate the expression of inflammatory factors, improve the disorder of inflammatory factor expression and reduce the damage to the body. At the same time, they can also increase the number of innate immune cells such as neutrophils and macrophages and improve their activity, thereby enhancing the body's innate immunity. Through the synergistic effect, it helps to comprehensively build and regulate the function of both adaptive and innate immune systems, thus achieving a comprehensive effect that helps to enhance immunity.

[0034] Furthermore, the nutrients mentioned in this invention, such as ω-6 polyunsaturated fatty acids like dihoxy-γ-linolenic acid and casein phosphopeptides, are all natural nutrients found in breast milk or cow's milk, suitable for long-term use, and readily accepted by people throughout their entire life cycle. The nutritional composition can be added to various types of products, including food, nutritional supplements, health foods, and pharmaceuticals. Detailed Implementation

[0035] The following describes embodiments of the present invention, but the present invention is not limited thereto. The present invention is not limited to the various configurations described below, and various modifications can be made within the scope of the claims. Embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention.

[0036] In this invention, "comprising," "having," "including," or "containing" can mean included or open-ended, and does not exclude additional, uncited elements or method steps. At the same time, "comprising," "having," "including," or "containing" can also mean closed-ended, excluding additional, uncited elements or method steps.

[0037] In this invention, the meaning of "may" includes both performing a certain process and not performing a certain process.

[0038] In this invention, the numerical ranges represented by "numerical value A - numerical value B" and "numerical value above / below A" refer to the ranges including the endpoints A and B.

[0039] In this invention, the term "about" is used to define that the numerical ranges and parameters of this invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as precisely as possible. Unless otherwise explicitly stated, it should be understood that all ranges, quantities, values, and percentages used in this invention are modified by the term "about". Here, "about" generally means that the actual value is within ±5%, ±3%, ±1%, or ±0.5% of a specific value or range. Furthermore, the values ​​and ranges appearing in this invention should be understood to include systematic errors that are unavoidable in industrial production.

[0040] In this invention, terms such as "some specific / preferred embodiments," "other specific / preferred embodiments," and "implementation" refer to specific elements (e.g., features, structures, properties, and / or characteristics) related to a particular embodiment that are included in at least one of the embodiments described herein, and may or may not be present in other embodiments. Furthermore, it should be understood that these elements may be combined in any suitable manner in various embodiments.

[0041] In this invention, all unit names used are international standard unit names, and unless otherwise stated, the "%" used refers to weight or mass percentage content.

[0042] In this invention, "infants and toddlers" refers to the human group under the age of 3 years, including infants aged 0-6 months, older infants aged 6-12 months, and toddlers aged 12-36 months.

[0043] In this invention, "children" refers to the human group aged 3-6 years.

[0044] In this invention, "teenagers" refers to the human group aged 7-18.

[0045] In this invention, "young adult" refers to the human group aged 19-40.

[0046] In this invention, "pregnant women" includes women who are pregnant and women who are breastfeeding.

[0047] In this invention, "middle-aged and elderly" refers to the human group aged 41 and above, including middle-aged people aged 41-65 and elderly people aged 65 and above.

[0048] In this invention, "animal milk" refers to the liquid obtained from the mammary glands of a mammal in the process of lactation.

[0049] Unless otherwise defined, other technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0050] This invention is mainly based on the following concept:

[0051] The immune system is the core defense line for the human body against pathogens and maintaining homeostasis. T cells, as the "central regulators" and "executors" of specific immunity, directly determine the effectiveness of the immune system's defenses. However, certain populations commonly exhibit T cell dysfunction. For example, immature T cell development in infants leads to immune vulnerability, while the decline in T cell function in middle-aged and elderly individuals results in immunosenescence. Existing nutritional compositions often focus on single or macroscopic immune manifestations, with few specifically targeting the development or improvement of T cell function to enhance immunity.

[0052] Based on this, the present invention aims to study how to achieve comprehensive immune system construction and functional regulation, especially for special groups such as infants and the elderly, and how to achieve synchronous development or reconstruction and functional regulation of non-specific immunity and specific immunity.

[0053] In response, this invention has discovered through extensive research that when ω-6 polyunsaturated fatty acids such as dihomo-γ-linolenic acid and casein phosphopeptide are combined, they can first promote the development, maturation and activation of T cells. Then, by regulating inflammatory factors, they can improve the body's inflammatory disorders and reduce the damage to the body. At the same time, they can regulate the number and activity of neutrophils and macrophages, enhance the body's innate immunity, and memory T cells can generate immune memory that can be rapidly activated when exposed to the same antigen again, providing long-term immune protection.

[0054] (Nutritional composition)

[0055] The nutritional composition provided by the present invention comprises the following two essential components: i) ω-6 polyunsaturated fatty acids, wherein the ω-6 polyunsaturated fatty acids include at least dihoxy-γ-linolenic acid; ii) casein phosphopeptide.

[0056] In this invention, "polyunsaturated fatty acid" refers to a straight-chain fatty acid with a chain length of 18 or more carbon atoms (C18) and containing two or more double bonds. "ω-6 polyunsaturated fatty acid" refers to a long-chain unsaturated fatty acid in which the first unsaturated double bond is located on the 6th carbon atom at the methyl end (i.e., the end furthest from the carboxyl group) of the fatty acid molecule.

[0057] This invention does not impose any special requirements on the source of ω-6 polyunsaturated fatty acids, as long as their source or form of use meets the requirements of local laws and regulations.

[0058] For example, ω-6 polyunsaturated fatty acids can be derived from plant-based ingredients such as sunflower seed oil, corn oil, and soybean oil, or from animal-based ingredients such as animal liver and animal milk.

[0059] In some embodiments, the carbon chain length of the ω-6 polyunsaturated fatty acid is C18-C22, preferably C20.

[0060] In some embodiments, the ω-6 polyunsaturated fatty acids of the present invention are used in the form of oils containing them, such as arachidonic acid oils obtained by bio-fermentation of Mortierella alpina. The content of dihoxy-γ-linolenic acid varies in different sources; for example, in arachidonic acid oils, the content of dihoxy-γ-linolenic acid is approximately 2%-30%.

[0061] Dihomo-γ-linolenic acid (DGLA), chemically named 8,11,14-cis-eicos-eicostrienoic acid, has the molecular formula C2. 20 H 34 O2, belonging to the n-6 series of polyunsaturated fatty acids, has the structural formula 20:3Δ8,11,14. This substance is a precursor to prostaglandin E1 and exerts its anti-atherosclerotic effect by inhibiting platelet aggregation. It accounts for approximately 20% of the total lipids in human plasma.

[0062] This invention does not specifically limit the source of alpha-gamma-linolenic acid. Typically, it can be prepared by microbial fermentation (such as Alpine spores), or extracted from substances rich in alpha-gamma-linolenic acid (such as arachidonic acid oil), or commercially available alpha-gamma-linolenic acid.

[0063] In this invention, "casein phosphopeptide" is a casein-derived peptide having at least one phosphoserine (SerP) residue.

[0064] This invention does not impose any special requirements on the source of casein phosphopeptides, as long as their source or form of use meets the requirements of local laws and regulations.

[0065] For example, casein phosphopeptides can be prepared by enzymatic hydrolysis of casein or casein acid salts, particularly whole casein, α-casein, κ-casein or β-casein, for example using trypsin, pepsin, chymotrypsin, pancreatin or bacterial (Bacillus), fungal or plant endogenous and / or exoproteases or mixtures thereof.

[0066] In some embodiments, the casein phosphopeptides of the present invention include at least one of casein phosphopeptides derived from cow's milk and casein phosphopeptides derived from sheep's milk, preferably casein phosphopeptides derived from cow's milk. Accordingly, casein phosphopeptides can be isolated and enzymatically hydrolyzed from cow's milk, or commercially available finished products can be purchased directly. For example, the casein phosphopeptide content in each source form can typically be 10%-99%.

[0067] In some embodiments, the nutritional composition comprises an active ingredient (a component that performs a specific physiological function, i.e., a component that helps enhance immunity, such as by contributing to the construction and regulation of the immune system) and an inactive ingredient (a substance that does not perform a function that helps enhance immunity, such as by contributing to the construction and regulation of the immune system, or at least does not perform a synergistic effect with dihydrogamma-linolenic acid or casein phosphopeptide). There are no particular limitations on the inactive ingredients that can also be used in the nutritional composition of the present invention. Exemplarily, without impairing the effects of the present invention, the inactive ingredient may be other nutrients, any food-acceptable excipient, and / or substances that are generated during the production or acquisition of the active ingredient and cannot be effectively separated from the active ingredient or do not need to be separated. In some embodiments, the nutritional composition consists of the active ingredient and the inactive ingredient.

[0068] In some embodiments, the active ingredients in the nutritional composition consist of ω-6 polyunsaturated fatty acids and casein phosphopeptides, which work synergistically to enhance immunity, such as by contributing to the building and regulation of the immune system.

[0069] In some embodiments, the active ingredients in the nutritional composition consist of dihydrogamma-linolenic acid and casein phosphopeptide, which work synergistically to enhance immunity, such as by contributing to the construction and functional regulation of the immune system.

[0070] In some embodiments, the nutritional composition further comprises ω-6 polyunsaturated fatty acids other than dihoxy-gamma-linolenic acid. Preferably, the ω-6 polyunsaturated fatty acids other than dihoxy-gamma-linolenic acid include at least one of linoleic acid, gamma-linolenic acid, and arachidonic acid. All of the above substances may be present in the nutritional composition as inactive ingredients.

[0071] In some embodiments, the mass ratio of the diamo-γ-linolenic acid to the casein phosphopeptide in the nutritional composition is 1:(1-3100), for example, it can be 1:1, 1:5, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:110, 1:120, 1:125, 1:130, 1:140, 1:150, 1:160, 1:170, 1:180, 1:190, 1: 200, 1:210, 1:220, 1:230, 1:240, 1:250, 1:260, 1:270, 1:280, 1:290, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1050, 1:1100, 1:1150, 1:1200, 1:12 50, 1:1300, 1:1350, 1:1400, 1:1450, 1:1500, 1:1515, 1:1550, 1:1600, 1:1650, 1:1700, 1:1750, 1:1800, 1:1850, 1:1900, 1:1950, 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, 1:3 The mass ratios are 1:3030, 1:3100, etc.; preferably, the mass ratio of the α-gamma-linolenic acid to the casein phosphopeptide is 1:(5-3100); more preferably, the mass ratio of the α-gamma-linolenic acid to the casein phosphopeptide is 1:(5-1000); even more preferably, the mass ratio of the α-gamma-linolenic acid to the casein phosphopeptide is 1:(5-500); and even more preferably, the mass ratio of the α-gamma-linolenic acid to the casein phosphopeptide is 1:(10-125). Within these mass ratio ranges, the α-gamma-linolenic acid and casein phosphopeptide synergistically enhance immunity, such as contributing to the construction and functional regulation of the immune system.

[0072] The present invention does not impose any particular limitation on the form of the nutritional composition; typically, it can be a liquid or a solid. From the perspective of ease of production, transportation, storage, and use, the nutritional composition of the present invention is preferably a powdered solid.

[0073] (Uses of the nutritional composition)

[0074] This invention provides the use of the above-described nutritional composition to enhance immunity, such as by contributing to the construction and functional regulation of the immune system. In some embodiments, the enhancement of immunity, such as by contributing to the construction and functional regulation of the immune system, is not for the purpose of preventing or treating disease; that is, this invention provides the non-therapeutic use of the above-described nutritional composition to enhance immunity, such as by contributing to the construction and functional regulation of the immune system. Based on this, this invention also provides the use of the above-described nutritional composition in the preparation of products that enhance immunity, such as by contributing to the construction and functional regulation of the immune system.

[0075] In some implementations, the ability to enhance immunity includes at least one of promoting T cell development, promoting T cell activation, balancing inflammatory factor levels, and increasing the number of innate immune cells.

[0076] In some implementations, the enhancement of immunity includes at least one of the following: increasing the expression levels of genes RAG1 and / or RAG2, increasing the expression levels of genes ZAP70 and / or IFNGR1, decreasing the level of TNF-α and / or increasing the level of IL-12α, and increasing the number of neutrophils and / or macrophages.

[0077] In some specific implementations, the enhancement of immunity includes promoting T cell development; preferably, promoting T cell development includes increasing the expression levels of genes RAG1 and / or RAG2; more preferably, promoting T cell development includes increasing the expression levels of genes RAG1 and RAG2; and even more preferably, promoting T cell development includes increasing the mRNA levels of genes RAG1 and RAG2.

[0078] In some specific implementations, the enhancement of immunity includes promoting T cell activation; preferably, promoting T cell activation includes increasing the expression levels of genes ZAP70 and / or IFNGR1; more preferably, promoting T cell development includes increasing the expression levels of genes ZAP70 and IFNGR1; and even more preferably, promoting T cell development includes increasing the mRNA levels of genes ZAP70 and IFNGR1.

[0079] In some specific implementations, the enhancement of immunity includes balancing the levels of inflammatory factors; preferably, balancing the levels of inflammatory factors includes reducing the level of TNF-α and / or increasing the level of IL-12α; more preferably, balancing the levels of inflammatory factors includes reducing the level of TNF-α and increasing the level of IL-12α; even more preferably, balancing the levels of inflammatory factors includes reducing the mRNA level of TNF-α and increasing the mRNA level of IL-12α.

[0080] In some specific implementations, the enhancement of immunity includes increasing the number of innate immune cells; preferably, increasing the number of innate immune cells includes increasing the number of neutrophils and / or macrophages; more preferably, increasing the number of innate immune cells includes increasing the number of neutrophils and macrophages.

[0081] In some preferred embodiments, the enhancement of immunity includes promoting T cell development, promoting T cell activation, balancing inflammatory factor levels, and increasing the number of innate immune cells.

[0082] Based on this, the present invention also provides the use of the above-mentioned nutritional composition in the preparation of products having one or more of the following effects (I) to (IV):

[0083] (I) Promoting T cell development; preferably, promoting T cell development includes increasing the expression levels of genes RAG1 and / or RAG2; more preferably, promoting T cell development includes increasing the expression levels of genes RAG1 and RAG2; even more preferably, promoting T cell development includes increasing the mRNA levels of genes RAG1 and RAG2;

[0084] (II) Promoting T cell activation; preferably, promoting T cell activation includes increasing the expression levels of genes ZAP70 and / or IFNGR1; more preferably, promoting T cell development includes increasing the expression levels of genes ZAP70 and IFNGR1; even more preferably, promoting T cell development includes increasing the mRNA levels of genes ZAP70 and IFNGR1.

[0085] (III) Balancing the levels of inflammatory factors; preferably, balancing the levels of inflammatory factors includes reducing the level of TNF-α and / or increasing the level of IL-12α; more preferably, balancing the levels of inflammatory factors includes reducing the level of TNF-α and increasing the level of IL-12α; even more preferably, balancing the levels of inflammatory factors includes reducing the mRNA level of TNF-α and increasing the mRNA level of IL-12α;

[0086] (IV) Increasing the number of innate immune cells; preferably, increasing the number of innate immune cells includes increasing the number of neutrophils and / or macrophages; more preferably, increasing the number of innate immune cells includes increasing the number of neutrophils and macrophages.

[0087] The present invention does not specifically limit the products containing or prepared from the above-described nutritional composition, such as food products. When the product is a food product, the components of the nutritional composition are used from sources or in forms that meet local legal and regulatory requirements.

[0088] In some implementation schemes, the food is infant food, children's food, adolescent food, pregnant and postpartum food, young and middle-aged food, or middle-aged and elderly food.

[0089] In some embodiments, the food product of this invention is a confectionery, such as hard candy, gel candy, shortbread candy, compressed candy, and aerated candy. In some embodiments, the food product of this invention is a beverage, such as carbonated beverages, tea beverages, coffee beverages, fruit and vegetable juice beverages, and lactic acid bacteria beverages. In some embodiments, the food product of this invention is a dairy product, such as milk powder, cheese, fermented milk, and liquid milk. In some embodiments, the food product of this invention is a baked product, such as bread, cakes, and biscuits. In some embodiments, the food product of this invention is a dietary supplement, such as hard capsules, soft capsules, tablets, oral liquids, pills, granules, and powders.

[0090] In some embodiments, the food described in this invention is in the form of a liquid or a solid under normal temperature conditions.

[0091] In some embodiments, the mass ratio of the dihydro-γ-linolenic acid to the casein phosphopeptide in the food is 1:(1-3100); preferably, the mass ratio can be 1:(5-3100); more preferably, the mass ratio can be 1:(5-1000); even more preferably, the mass ratio can be 1:(5-500); and even more preferably, the mass ratio can be 1:(10-125).

[0092] This invention does not impose any specific absolute limits on the content of dihydroxy-γ-linolenic acid and casein phosphopeptide in food, as long as the requirements of local food-related laws and regulations are met.

[0093] In some embodiments, the content of dihydro-γ-linolenic acid in the food may be 0.005 mg / 100g-50 mg / 100g, based on the total dry matter content of the food; and the content of casein phosphopeptide may be 20 mg / 100g-500 mg / 100g.

[0094] In addition to the components described above in the nutritional composition, the food may also contain other ingredients, such as common food ingredients like proteins / amino acids, carbohydrates, fats, vitamins, and minerals.

[0095] In addition, depending on the type of food and the end needs of the target audience, in some embodiments, the food may also contain one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and any acceptable excipients.

[0096] Examples of plant-based ingredients include fruits such as figs, pomegranates, kiwis, oranges, tangerines, pineapples, strawberries, apples, bananas, grapes, pears, cherries, blueberries, blackberries, blackcurrants, cranberries, raspberries, melons, amla, and bilberries, or their extracts; vegetables such as onions, cucumbers, tomatoes, cauliflower, carrots, spinach, kale, Brussels sprouts, garlic, basil, and oregano, or their extracts; grains such as rice (indica, japonica, glutinous rice), cereals (wheat, barley, oats, rye), corn, sorghum, millet, sorghum, yellow millet, buckwheat, soybeans, broad beans, peas, mung beans, red beans, and kidney beans, or their extracts; nuts such as walnuts, pistachios, cashews, hazelnuts, almonds, apricot kernels, pine nuts, peanuts, sunflower seeds, chestnuts, macadamia nuts, and ginkgo nuts, or their extracts; coffee or its extracts; and some medicinal and edible herbal medicines or their extracts.

[0097] Animal dairy product ingredients can include fresh milk from mammals such as cows, sheep, and camels, as well as reprocessed dairy products such as whole milk powder, skim milk powder, whey protein concentrate, desalted whey powder, whey protein powder, hydrolyzed whey protein powder, and casein powder.

[0098] Examples of animal meat product ingredients include pork, beef, mutton, seafood, and poultry.

[0099] Examples of functional additives include vitamin supplements (such as vitamin A, beta-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, and vitamin B1). 12 Supplements include: Vitamin C, pantothenic acid, folic acid, niacin, biotin, etc.; mineral supplements (e.g., calcium, iron, copper, manganese, zinc, magnesium, fluorine, sodium, potassium, selenium, iodine, etc.); nucleotide supplements (e.g., disodium 5'-cytidine, disodium 5'-uridine, adenosine monophosphate, disodium 5'-guanylate, disodium 5'-inosine, etc.); dietary fiber (e.g., inulin, konjac flour, galactooligosaccharides, fructooligosaccharides, isomaltooligosaccharides, soybean polysaccharides, cyclodextrin, resistant dextrin, soybean fiber, etc.); and polyunsaturated fatty acid supplements (e.g., docosahexaenoic acid oil powder, etc.).

[0100] Any acceptable excipients may include solvents, antioxidants, antibacterial agents, thickeners, diluents, cosolvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coating materials, anti-caking agents, flavoring agents, sweeteners, food flavorings, and food colorings.

[0101] Example

[0102] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.

[0103] The experimental instruments used in the experimental examples of this invention include: a zebrafish recirculating aquaculture system (ESEN-AW-S1, Beijing Aisheng Technology Development Co., Ltd.); an electronic balance (AR-2140, Shanghai Ohaus Instrument Co., Ltd.); an ultrapure water system (TC-RO-100, Shanghai Likang Instrument Co., Ltd.); a pH meter (pH9500, Shanghai Peirui Instrument Co., Ltd.); a conductivity meter (HM-100TDS, HM Digital Co., Ltd., South Korea); a high-precision thermometer (Odasys Technology Co., Ltd.); an ultra-low temperature freezer (HYCD-205, Qingdao Haier Co., Ltd.); a high-speed refrigerated centrifuge (Micro 21R, Thermo Fisher Scientific, USA); a mini centrifuge (LX-500, Anhui Zhongke Co., Ltd.); a real-time quantitative PCR system (7500Fast, Thermo Fisher Scientific, USA); and an ultra-micro spectrophotometer (ND5000, Wuxi Baitai Biotechnology Co., Ltd.).

[0104] The experimental materials used in the experimental examples of this invention include: E3 culture medium (5mM sodium chloride, 0.17mM potassium chloride, 0.33mM calcium chloride, 0.33mM magnesium sulfate) purchased from Beijing Chemical Reagent Company; cyclophosphamide (Shanghai Maclean Biochemical Technology Co., Ltd.); levamisole (Shanghai Maclean Biochemical Technology Co., Ltd.); dihydro-γ-linolenic acid (DGLA, C20:3n-6, Shanghai Maclean Biochemical Technology Co., Ltd.); and casein phosphopeptide (CPP, provided by Heilongjiang Feihe Dairy Co., Ltd.).

[0105] The experimental animals used in the experimental examples of this invention include wild-type AB strain zebrafish, which were raised and maintained by the Precision Nutrition and Active Health Center of Yantai University.

[0106] (1) Rearing environment: Adult zebrafish were raised in a zebrafish recirculating aquaculture system, with 14h / 10h (light / dark) per day, water temperature maintained at 28±0.5℃, pH 7.0-8.0, and conductivity around 500μs. Fresh brine shrimp eggs were fed twice a day.

[0107] (2) Zebrafish spawning: Remove the mating box, insert a separator in the middle to separate the males and females, add circulating water to the system until it is 80% full, and finally place it in the isolation tank to prevent the adult fish from eating the embryos. After the adult zebrafish finish feeding at night, place them on both sides of the separator according to the ratio of male to female fish of 1:2. The next morning, remove the separator. After the male and female fish chase each other, they will lay eggs and fertilize externally. After 0.5-1 hour, collect the adult fish into the circulating water system and mark the date. Use a filter to collect the embryos in a glass culture dish containing E3 water and culture them at 28±0.5℃.

[0108] Experiment Example 1: Effects of different nutrients and combinations on the development of lymphocytes and T cells

[0109] The immune system plays a crucial role in maintaining homeostasis, defending against pathogen invasion, and responding to adverse external stimuli. Cyclophosphamide (CTX) is a classic alkylating immunosuppressant that exhibits significant toxicity to rapidly dividing immune cells by interfering with DNA synthesis, inhibiting cell proliferation, and inducing apoptosis. CTX also significantly inhibits lymphocyte production and differentiation, disrupting the normal development and function of the immune system, thereby leading to a decreased immune response. Therefore, CTX is often used to construct stable and reproducible animal models of immune dysfunction or immunodeficiency.

[0110] In this experiment, the effect of different concentrations of cyclophosphamide on the survival rate of zebrafish was first investigated. The results showed that the survival rate of zebrafish was still 100% when the maximum concentration of cyclophosphamide was 2.5 mM. When the concentration was further increased to 5 mM, the survival rate dropped to 82%. When the concentration was further increased to 10 mM, the survival rate of zebrafish was 0. Therefore, in subsequent experiments, the cyclophosphamide treatment concentration of 2.5 mM was uniformly selected.

[0111] In addition, before studying the immune-enhancing function, the toxicity and lethality of the monomers and combinations of the two nutrients to zebrafish were investigated. This study found that the survival rate of DGLA at three concentrations (0.033 μg / mL, 0.2 μg / mL, and 0.4 μg / mL), and CPP at three concentrations (2 μg / mL, 50 μg / mL, and 100 μg / mL), as well as in eight different combinations formed by combining the two in different proportions, was 100%, and no other toxicity was observed. This indicates that the concentrations of the two nutrient monomers used in this experiment, and their synergistic combinations, do not pose a toxic threat to zebrafish and do not affect their survival rate.

[0112] 1. Construction and experimental grouping of a model of low immunity in zebrafish juveniles

[0113] Wild-type AB zebrafish (4 dpf) were randomly selected and placed in 6-well plates, 30 fish per well. A blank control group, a model group, a positive control group, and a sample treatment group were set up. The blank control group was cultured normally in E3 water (without any other treatment or intervention). All other groups were treated with 2.5 mM cyclophosphamide, and the model group received no further intervention. The positive control group was treated with 25 μg / mL levamisole. The sample treatment groups received different nutrient interventions.

[0114] In this study, DGLA and CPP were selected for different single doses or different ratios to investigate their synergistic effect in improving immunodeficiency. The experimental design is shown in Table 1. The blank control group consisted of normal zebrafish without any treatment or intervention; the model group consisted of zebrafish treated with 2.5 mM cyclophosphamide, specifically 2.5 mM cyclophosphamide was dissolved in E3 water, and then 3 mL was placed in the wells of a 6-well plate to feed the zebrafish; the positive control group consisted of zebrafish treated with 2.5 mM cyclophosphamide + 25 μg / mL levamisole, specifically 2.5 mM cyclophosphamide was dissolved in E3 water, and then 25 μg / mL levamisole was dissolved in the same solution, and then 3 mL was placed in the wells of a 6-well plate to feed the zebrafish. The sample treatment group consisted of zebrafish treated with 2.5 mM cyclophosphamide and nutrients. Specifically, cyclophosphamide was dissolved in E3 water, and the sample to be tested was then dissolved in the solution. 3 mL of the solution was then placed in the wells of a 6-well plate containing the zebrafish and fed to them. Comparative Examples 1-3 involved 2.5 mM cyclophosphamide and different concentrations of DGLA alone (0.033 μg / mL, 0.2 μg / mL, and 0.4 μg / mL); Comparative Examples 4-6 involved 2.5 mM cyclophosphamide and different concentrations of CPP alone (2 μg / mL, 50 μg / mL, and 100 μg / mL); Examples 1-8 involved combined intervention with compositions of 2.5 mM cyclophosphamide, DGLA, and CPP in different ratios (1:5-3030).

[0115] Table 1. Experimental Intervention Design

[0116]

[0117] 2. qPCR method for analyzing immune-related genes

[0118] Wild-type AB strain zebrafish with a 4dpf cell count were randomly selected and randomly assigned to 6-well plates, with 30 zebrafish treated in each well (experimental group). After treatment at 28℃ for 24 h, all 30 zebrafish from each well were collected into 2 mL RNase-free centrifuge tubes, the water was aspirated, and 350 μL of pre-chilled lysis buffer (Ciscotech, catalog number: AC0202-B) and 2 sterilized 3 mm steel balls were added. The cells were then lysed in a cell disruptor at 4℃.

[0119] Total RNA was extracted using the Cisco SPARKeasy RNA Rapid Extraction Kit. The simplified steps included: lysis followed by mixing with anhydrous ethanol, transferring to an adsorption column, centrifuging, and discarding the eluent; washing the adsorption column sequentially with washing buffer; and finally eluting RNA with RNase-free water. RNA concentration and purity were determined using a micro-spectrophotometer. An A260 / A280 ratio of 1.8–2.0 was considered acceptable. Acceptable samples were stored at -80°C for later use.

[0120] Equal amounts of total RNA were used to synthesize cDNA using a Cisco reverse transcription kit. Genomic DNA was first removed by treatment with a gDNA Eraser at 42°C for 2 min, followed by the addition of SPARKscript II RT Plus Master Mix. The reaction was then terminated by heating at 85°C for 5 sec. The cDNA product was stored at -20°C.

[0121] The mRNA expression level of the gene was detected using the Cisco Real-Time Quantitative PCR Kit.

[0122] The reaction mixture (20 μL) consisted of 10 μL of 2×SYBR qPCR Mix, 0.4 μL each of forward and reverse primers, 1 μL of cDNA template, and 8.2 μL of RNase-free H2O. Each sample was tested in triplicate. Gene expression levels were calculated using the 2-ΔΔCt method after normalization with an internal control gene. Primer sequences are shown in Table 2.

[0123] Experimental data are expressed as mean ± standard deviation. One-way ANOVA was performed using GraphPad Prism software, and Dunnett's test was used for comparisons between groups. p < 0.05 was considered statistically significant.

[0124] Table 2. Primer sequences

[0125]

[0126] 3. Results of T cell development-related gene expression detection

[0127] Nutrients can significantly upregulate the mRNA expression and protein activity of RAG1 and RAG2 by activating T cell development signaling pathways (such as the Notch signaling pathway) within the thymus. RAG1, as the core catalytic subunit for T cell receptor (TCR) gene rearrangement, forms a recombination complex with RAG2, which can specifically recognize and cleave TCR gene fragments, promoting V(D)J rearrangement efficiency. The synergistic effect of both can increase the number of mature T cells (CD4+). + / CD8 + The amount of T cells produced.

[0128] This invention found that the expression levels of RAG1 and RAG2 genes in zebrafish were significantly lower than those in the blank control group after cyclophosphamide induction, while the expression levels of both key genes were upregulated after levamisole intervention. The experimental results are shown in Table 3, and the significance analysis of differences between groups is shown in Table 4. Table 3 shows that comparative examples 1-3 showed that DGLA intervention alone increased the expression levels of RAG1 and RAG2 genes to varying degrees, and both increased with increasing DGLA concentration. Comparative example 3 showed the highest increase in the expression levels of these two genes, and the significance analysis revealed that the expression levels of both genes in all three comparative examples were significantly higher than those in the model group (p values ​​are shown in Table 4). This indicates that DGLA intervention alone can increase the expression levels of RAG1 and RAG2 genes in zebrafish. Comparative examples 4-6 showed that CPP intervention alone also increased the expression levels of RAG1 and RAG2 genes to some extent, also showing a trend of increasing with increasing intervention dose. After significant difference analysis, it was found that the expression levels of two genes in the three comparative examples were significantly higher than those in the model group (p values ​​are shown in Table 4), indicating that CPP intervention alone can also increase the expression levels of RAG1 and RAG2 genes in zebrafish. Examples 1-8 showed that combined intervention with the two nutrients in different proportions further increased the expression levels of RAG1 and RAG2 genes in zebrafish. Among them, the expression level of RAG1 gene was the highest in Example 1 (approximately 0.953), while the expression level was the lowest in Example 2 (approximately 0.824); similarly, the expression level of RAG2 gene was the highest in Example 1 (approximately 0.961), while the expression level was the lowest in Example 2 (approximately 0.802). Further analysis revealed that the expression levels in all eight examples were significantly higher than those in the model group and significantly higher than those in the six comparative examples (p values ​​are shown in Table 4), indicating that the combined intervention of DGLA and CPP is more effective than the intervention of the two nutrients alone. Further analysis revealed that the effects of the eight examples on the expression levels of RAG1 and RAG2 genes were significantly higher than the direct sum of the effects of the interventions at the same individual doses compared to the model group. This indicates that the two nutrients, DGLA and CPP, played a synergistic role.

[0129] This part of the study shows that a combination of DGLA and CPP in a ratio of 1:5-3030 can promote T cell development and maturation, increase the "functional T cell pool that can recognize pathogens", and lay the foundation for immune cell reserves.

[0130] Table 3. Effects of different monomers and nutrient combinations on the expression levels of T cell development-related genes.

[0131]

[0132] Table 4. Significant differences among zebrafish groups in the expression levels of T cell development-related genes.

[0133]

[0134]

[0135] Experiment Example 2: Effects of different nutrients and combinations on T cell activation

[0136] 1. The model of low immunity in zebrafish juveniles and the experimental grouping were the same as in Experiment 1.

[0137] 2. The qPCR method was used to analyze immune-related genes, as in Experiment 1.

[0138] 3. Experimental Results

[0139] T cell activation is a crucial turning point in the transition of T cells from a "resting state" to a "functional state." It is a core link connecting "T cell development and maturation" with "immune effector output," and its role directly determines the efficiency, intensity, and direction of the immune response. This invention uses two core indicators, ZAP70 and IFNGR1, to examine the effects of different nutrient interventions on T cell activation.

[0140] ZAP70 is a core kinase in the T cell antigen receptor (TCR) signaling pathway. After TCR recognizes an antigen, it can be recruited by the CD3ζ chain and undergo tyrosine phosphorylation. Enhanced binding efficiency of ZAP70 to the CD3ζ chain promotes the activation of downstream LAT and PLC-γ1 molecules, ensuring the transformation of T cells from a "resting state" to an "activated state." In this invention, ZAP70 was used as a standard for T cell activation. As shown in Table 5, the expression level of ZAP70 gene in zebrafish after cyclophosphamide modeling was significantly lower than that in the blank control group (p < 0.0001), while the expression level of ZAP70 gene was significantly increased to the level of the blank control group after levamisole intervention. As shown in Table 5, Comparative Examples 1-3 demonstrate that the expression level of the ZAP70 gene increased continuously with the increase of the intervention concentration after DGLA intervention alone. Furthermore, after significant difference analysis, all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 6), indicating that DGLA intervention alone can increase the expression level of the ZAP70 gene in zebrafish. Comparative Examples 4-6 show that the expression level of the ZAP70 gene also increased to varying degrees after CPP intervention alone. After significant difference analysis, all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 6), indicating that CPP intervention alone can also increase the expression level of the ZAP70 gene in zebrafish. Examples 1-8 show that when the two nutrients are combined in different proportions, the combined intervention further increases the expression level of the ZAP70 gene in zebrafish compared to the comparative examples. In particular, the expression level reached a maximum of 0.920 in Example 1 and a minimum of 0.794 in Example 2. Analysis of significant differences revealed that all eight examples showed significantly higher levels than the model group and significantly higher levels than the six comparative examples (p-values ​​shown in Table 6). This indicates that the combined intervention of DGLA and CPP is more effective than intervention by either nutrient alone. Further analysis showed that the effects of the eight examples on ZAP70 gene expression were significantly greater than the sum of the effects of interventions at the same individual doses compared to the model group. This suggests that the two nutrients, DGLA and CPP, have a synergistic effect. This implies that the synergistic effect of the two nutrients can fully open the T cell receptor (TCR) signaling pathway, allowing mature T cells to respond rapidly to antigens and avoiding "immune sluggishness."

[0141] IFNGR1, as the α-chain receptor for interferon-γ (IFN-γ), directly determines the T cell's ability to receive IFN-γ signals. Nutrients can activate the JAK-STAT pathway, promoting the localized expression of IFNGR1 on the T cell membrane, enhancing the T cell's sensitivity to IFN-γ, and further amplifying activation signals (such as promoting T cell proliferation). This invention found that after cyclophosphamide modeling, the IFNGR1 gene expression level in zebrafish was significantly lower than that in the blank control group (p < 0.0001), while after levamisole intervention, the IFNGR1 gene expression level significantly increased back to the blank control group level. As can be seen from Table 5, Comparative Examples 1-3 showed that the expression level of the IFNGR1 gene increased continuously with the increase of the intervention concentration after DGLA intervention alone. However, after the difference significance analysis, it was found that there was no significant difference between Comparative Example 1 and the model group (p>0.05), while Comparative Examples 2 and 3 were significantly higher than the model group (p values ​​are shown in Table 6). This indicates that DGLA intervention alone at a certain dose can increase the expression level of the IFNGR1 gene in zebrafish. Comparative Examples 4-6 showed that the expression level of the IFNGR1 gene also increased to varying degrees after CPP intervention alone. After the difference significance analysis, it was found that all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 6). This indicates that CPP intervention alone can also increase the expression level of the IFNGR1 gene in zebrafish. Examples 1-8 showed that when the two nutrients were combined in different proportions, the combined intervention further increased the expression level of the IFNGR1 gene in zebrafish compared with the comparative examples. In particular, the expression level in Example 1 reached the highest of 0.983, while the lowest (approximately 0.841) was observed in Example 3. Analysis of significant differences revealed that all eight examples showed significantly higher levels than the model group and significantly higher levels than the six comparative examples (p-values ​​shown in Table 6). This indicates that the combined intervention of DGLA and CPP is more effective than intervention by either nutrient alone. Further analysis showed that the effects of the eight examples on IFNGR1 gene expression were significantly greater than the direct sum of the effects of interventions at the same individual doses compared to the model group. This suggests that the two nutrients, DGLA and CPP, have a synergistic effect, implying that the synergistic effect of the two nutrients enhances the activation efficiency and functional direction of T cells.

[0142] Table 5. Effects of different monomers and nutrient compositions on the expression levels of T cell activation-related genes.

[0143]

[0144] Table 6. Significant differences among zebrafish groups in the expression levels of T cell activation-related genes.

[0145]

[0146]

[0147] Experiment Example 3: Effects of different nutrients and their combinations on the expression of inflammatory factors in the body

[0148] 1. The model of low immunity in zebrafish juveniles and the experimental grouping were the same as in Experiment 1.

[0149] 2. The qPCR method was used to analyze immune-related genes, as in Experiment 1.

[0150] 3. Experimental Results

[0151] Inflammatory factors are a core effector mechanism in the immune function of T cells. After promoting T cell development, maturation, and activation, inflammatory factors are the manifestation of T cells converting intracellular activation signals into a systemic immune response, reflecting their ability to fight pathogens or regulate other immune cells. In this invention, the effects of DGLA and CPP monomers and compositions on two inflammatory factors, tumor necrosis factor-α (TNF-α) and interleukin-12α subunit (IL-12α), were investigated. The experimental results are shown in Table 7, and the results of the significance analysis between groups are shown in Table 8.

[0152] Tumor necrosis factor-α (TNF-α) is mainly secreted by activated macrophages, T cells, NK cells, mast cells, and certain tissue cells (such as adipocytes). TNF-α is a core initiator of the inflammatory cascade, potently pro-inflammatory and inducing apoptosis, playing a crucial role in autoimmune diseases, sepsis, and metabolic diseases. This invention first investigated the effects of DGLA and CPP monomers and combinations on the expression level of the inflammatory cytokine TNF-α gene in immunodeficient zebrafish. As shown in Table 7, the expression level of TNF-α gene in zebrafish in the immunodeficient model group increased to 1.51. After one-way ANOVA, a significant difference was found between the model group and the blank control group (p < 0.0001). However, after intervention with levamisole, the expression level of TNF-α gene decreased to 1.04, indicating that levamisole intervention inhibited the initiation and outbreak of the inflammatory cytokine TNF-α. The effects of DGLA and CPP at different individual doses and in different proportions on the expression level of TNF-α gene in zebrafish after modeling were further investigated. As shown in Table 7, DGLA alone reduced TNF-α gene expression to some extent after intervention (Comparative Examples 1-3). Statistical analysis revealed no significant difference between Comparative Example 1 and the model group (p > 0.05), while Comparative Examples 2 and 3 were significantly lower than the model group (p values ​​are shown in Table 8). This indicates that DGLA alone at a certain dose can reduce TNF-α gene expression. Comparative Examples 4-6 showed that CPP alone also reduced TNF-α gene expression to varying degrees, and statistical analysis revealed that all three comparative examples were significantly lower than the model group (p values ​​are shown in Table 8). Examples 1-8 showed that combined intervention with different proportions of the two nutrients further enhanced the effect, further reducing TNF-α gene expression levels, with the lowest value being 1.037 (Example 1). Statistical analysis revealed that all eight examples were significantly lower than the model group and significantly lower than the six comparative examples (p values ​​are shown in Table 8). This indicates that the combined intervention of DGLA and CPP is more effective than intervention with either nutrient alone. Further analysis revealed that the effects of the eight embodiments on the inflammatory factor TNF-α were significantly higher than the direct sum of the effects of the interventions at the same individual doses compared to the model group. This indicates that the two nutrients, DGLA and CPP, have a synergistic effect. This suggests that the combination of DGLA and CPP can reduce the occurrence of chronic inflammation, tissue damage, immune exhaustion, and metabolic disorders caused by persistently high TNF-α expression.

[0153] Interleukin-12 (IL-12) is a key cytokine primarily secreted by antigen-presenting cells (APCs), such as monocytes, macrophages, and dendritic cells, in response to infection or inflammation. IL-12 activates NK cells and T cells, promotes Th1 cell differentiation, bridges innate and adaptive immunity, has anti-tumor and anti-infection effects, and enhances memory T cell function. In the later stages of infection, it can improve the immune system's ability to prevent subsequent infections by promoting the generation and maintenance of memory T cells. IL-12α and IL-12β together form IL-12, a key guiding factor for regulating the direction of T cell function. Insufficient expression of IL-12α leads to impaired Th1 cell differentiation, resulting in T cells being activated but their functional direction being deviated. Table 7 shows that the expression level of IL-12α gene in zebrafish in the immunocompromised model group was significantly lower than that in the blank control group (p < 0.0001), while the expression level of IL-12α gene increased to 1 after intervention with levamisole, indicating that levamisole intervention promoted the expression of IL-12α. Further investigation was conducted on the effects of different doses of DGLA and CPP monomers and combinations of the two in different ratios on the expression level of IL-12α gene in zebrafish after modeling. As shown in Table 7, DGLA intervention alone (Comparative Examples 1-3) resulted in varying degrees of increase in IL-12α gene expression, which increased continuously with increasing DGLA concentration. Significant difference analysis revealed that all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 8), indicating that DGLA intervention alone can significantly increase IL-12α gene expression. Comparative Examples 4-6 showed that CPP intervention alone also resulted in varying degrees of increase in IL-12α gene expression. Significant difference analysis revealed that all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 8), indicating that CPP intervention alone can also increase IL-12α gene expression. Examples 1-8 showed that the combined intervention of the two nutrients in different proportions further enhanced the effect, with the highest IL-12α gene expression level reaching 0.950 (Example 1). Significant difference analysis revealed that all eight examples were significantly higher than the model group and significantly higher than the six comparative examples (p values ​​are shown in Table 8), indicating that the combined intervention of DGLA and CPP is more effective than the intervention of either nutrient alone. Further analysis revealed that the effects of the eight embodiments on the inflammatory factor IL-12α were significantly higher than the direct sum of the effects of the interventions at the same single dose compared to the model group. This indicates that the two nutrients, DGLA and CPP, have a synergistic effect. This means that the combination of the two nutrients, DGLA and CPP, can promote the expression of the important positive immune regulatory factor IL-12α, indicating enhanced immune defense function, improving the body's immune function, and without causing excessive inflammatory damage.

[0154] Table 7. Effects of different monomers and nutritional combinations on the expression levels of inflammatory factor genes.

[0155]

[0156] Table 8. Significant differences in the expression levels of inflammatory factor genes in zebrafish among different groups.

[0157]

[0158]

[0159] Experiment Example 4: Effects of different nutrients and combinations on the body's innate immune cells

[0160] 1. The model of low immunity in zebrafish juveniles and the experimental grouping were the same as in Experiment 1.

[0161] 2. Detection Method

[0162] 2.1 Neutrophil detection (Sudan Black B staining method)

[0163] Three days after nutrient intervention, 7-day-fed juvenile zebrafish were harvested, washed 2-3 times with PBS, and then fixed overnight in freshly prepared 4% paraformaldehyde (PFA) at 4°C in the dark using a shaker. After fixation, the samples were washed 3 times with PBS (5 min each time). Subsequently, under dark conditions at room temperature, the samples were gently stained in Sudan Black B working solution with shaking for 1.5-2 h. After staining, the samples were washed 3 times with 70% ethanol (5-10 min each time) to remove unbound dye, and then rehydrated twice with PBS-Tween (1×PBS + 0.1% Tween-20). The samples were then transferred to KOH / H2O2 destaining solution and treated at room temperature for 5-10 min. The degree of melanin removal was monitored under a microscope, followed by washing twice with PBS-Tween to stabilize the signal. After decolorization, the juvenile fish were preserved in PBS and single-plane horizontal scanning imaging (xy plane) was performed using a laser confocal microscope with a water immersion objective (10×). Z-stick scanning was not performed, and only the distribution of neutrophils within the same focal plane was observed and analyzed.

[0164] 2.2 Macrophage detection (Neutral Red staining)

[0165] Three days after nutrient intervention, 7-day-flash (dpf) wild-type zebrafish juveniles were harvested. Neutral Red was dissolved in E3 culture medium to prepare a 2.5 μg / mL working solution under light-protected conditions. The juveniles were transferred to the dye-containing E3 solution and incubated at 28.5°C in the dark for 6-8 hours. After staining, the fish were washed 2-3 times with fresh E3 water to remove excess dye, and then anesthetized for 1-2 minutes with 0.2 mg / mL Tricaine (MS-222, buffered with NaHCO3 to pH 7.0-7.4). Subsequently, observation and imaging were performed using a stereomicroscope. The red spots appearing in the juvenile fish represented the accumulation signal of Neutral Red in macrophages within lysosomes, used to assess the number and distribution of macrophages.

[0166] 3. Experimental Results

[0167] Activated T cells do not function in isolation; instead, they secrete pro-inflammatory factors to provide "activation signals" to innate immune cells (such as neutrophils and macrophages), thereby achieving synergistic enhancement of innate immune cells. Neutrophils are the main force in acute infections, responding rapidly but with a short lifespan, primarily responsible for phagocytizing and eliminating pathogens. Macrophages have a more enduring role, participating in antigen presentation and tissue repair in addition to phagocytizing and degrading cell debris and pathogens, and can regulate immune responses by releasing cytokines. This experiment investigated the effects of DGLA and CPP, in monomeric or combined forms, on innate immune cells in zebrafish. The results are shown in Table 9, and the analysis of significant differences between groups is shown in Table 10.

[0168] As shown in Table 9, the average fluorescence intensity of neutrophils in the blank control group was 104, while the number of neutrophils decreased significantly after cyclophosphamide modeling, and the fluorescence intensity dropped to 41.33. The difference was statistically significant after one-way ANOVA analysis (p < 0.0001). After intervention with levamisole, the fluorescence intensity of neutrophils recovered to about 102. Comparative Examples 1-3 showed that the mean fluorescence intensity of neutrophils increased with increasing DGLA concentration after intervention alone. However, after significance analysis, it was found that there was no significant difference between the low-dose intervention (Comparative Example 1) and the model group (p>0.05), while the medium- and high-dose interventions (Comparative Examples 2 and 3) were significantly higher than the model group (p values ​​are shown in Table 10). This indicates that DGLA intervention alone can significantly increase the number of neutrophils after reaching a certain dose. Comparative Examples 4-6 showed that the mean fluorescence intensity of neutrophils also increased after CPP intervention alone, but the low-dose intervention (Comparative Example 4) showed a significant increase. The increase in neutrophil fluorescence intensity was relatively low. After significant difference analysis, all three comparative examples showed significantly higher levels than the model group (p-values ​​are shown in Table 10), indicating that CPP alone had a certain effect on increasing neutrophil count. Examples 1-8 showed that the combined intervention of the two nutrients in different proportions further enhanced the effect, with the highest neutrophil fluorescence intensity reaching 93.67 (Example 1). Significant difference analysis revealed that all eight examples were significantly higher than the model group and significantly higher than the six comparative examples (p-values ​​are shown in Table 10), indicating that the combined intervention of DGLA and CPP was superior to the intervention of either nutrient alone. Further analysis showed that the increase in neutrophil fluorescence intensity in the eight examples compared to the model group was significantly higher than the direct sum of the intervention effects at the same individual doses, indicating that the two nutrients, DGLA and CPP, had a synergistic effect.

[0169] As can also be seen from Table 9, the average fluorescence intensity value of the reaction macrophages in the blank control group zebrafish was 100.33, while after cyclophosphamide modeling, the number of macrophages was significantly reduced, and the fluorescence intensity decreased to 14.67. After one-way ANOVA, the difference between the two was found to be significant (p < 0.0001). After intervention with levamisole, the fluorescence intensity of macrophages recovered to 92. Comparative Examples 1-3 showed that the average fluorescence intensity of macrophages increased to the range of 23.33-39 after DGLA intervention alone. After significant difference analysis, all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 10), indicating that DGLA intervention alone can increase the number of macrophages. Comparative Examples 4-6 showed that the average fluorescence intensity of macrophages increased to the range of 22-33.33 after CPP intervention alone. Comparative Example 4 showed a lower increase, but after significant difference analysis, all three comparative examples were significantly higher than the model group (p values ​​are shown in Table 10), indicating that CPP intervention alone can also increase the number of macrophages. Examples 1-8 showed that the combined intervention of the two nutrients in different proportions further enhanced the effect, with the highest macrophage fluorescence intensity reaching 68.67 (Example 1). After significant difference analysis, all eight examples were significantly higher than the model group and significantly higher than the six comparative examples (p values ​​are shown in Table 10), indicating that the combined intervention of DGLA and CPP is more effective than the intervention of either nutrient alone. Further analysis revealed that the improvement in macrophage fluorescence intensity in the eight examples was significantly higher than the direct sum of the intervention effects at the same individual doses compared to the model group, indicating that the two nutrients, DGLA and CPP, played a synergistic role.

[0170] Table 9. Effects of different monomers and nutritional compositions on immune cells

[0171]

[0172] Table 10. Analysis of significant differences in immune cells among zebrafish groups

[0173]

[0174]

Claims

1. A nutritional composition, characterized in that, The nutritional composition comprises the following two essential components: i) ω-6 polyunsaturated fatty acids, wherein the ω-6 polyunsaturated fatty acids include at least dihomo-γ-linolenic acid; ii) Casein phosphopeptides; Furthermore, in the nutritional composition, the mass ratio of the dihydro-γ-linolenic acid to the casein phosphopeptide is 1:(1-3100).

2. The nutritional composition according to claim 1, characterized in that, The ω-6 polyunsaturated fatty acids are provided in the form of oils containing them.

3. The nutritional composition according to claim 1 or 2, characterized in that, The casein phosphopeptide includes at least one casein phosphopeptide derived from cow's milk and sheep's milk.

4. The nutritional composition according to any one of claims 1-3, characterized in that, The carbon chain length of the ω-6 polyunsaturated fatty acid is 18-22 carbon atoms.

5. The nutritional composition according to any one of claims 1-4, characterized in that, The ω-6 polyunsaturated fatty acids also include at least one of linoleic acid, γ-linolenic acid, and arachidonic acid.

6. Use of the nutritional composition according to any one of claims 1-5 in the preparation of products that help enhance immunity; wherein, The benefits of boosting immunity include aiding in the construction and regulation of the immune system.

7. The use according to claim 6, characterized in that, The benefits of enhancing immunity include at least one of the following: promoting T cell development, promoting T cell activation, balancing inflammatory factor levels, and increasing the number of innate immune cells.

8. The use according to claim 6 or 7, characterized in that, The ability to enhance immunity has one or more of the following characteristics (I) to (IV): (I) Increase the expression levels of genes RAG1 and / or RAG2; (II) Increase the expression levels of genes ZAP70 and / or IFNGR1; (III) Decrease TNF-α levels and / or increase IL-12α levels; (IV) Increase the number of neutrophils and / or macrophages.

9. The use according to any one of claims 6-8, characterized in that, The product is either solid or liquid.

10. The use according to any one of claims 6-9, characterized in that, The product contains any one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and any acceptable excipients.

Citation Information

Patent Citations

  • A functional composition with immunomodulatory effects, its preparation method and application

    CN114831317B

  • Functional nutritional composition and use thereof

    CN117441900B